Toxicologic Pathology

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Register here to gain access to SAGE's 500+ Journals Online

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mohrenweiser, H. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mohrenweiser, H. W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Toxicologic Pathology, Vol. 32, No. 1 suppl, 136-145 (2004)
DOI: 10.1080/01926230490424671

Genetic Variation and Exposure Related Risk Estimation: Will Toxicology Enter a New Era? DNA Repair and Cancer as a Paradigm

Harvey W. Mohrenweiser

Biology and Biotechnology Research Program, Lawrence Livermore National Laboratory, Livermore, California, USA, hmohrenw{at}uci.edu

With the vast technological and informational resources increasingly available from investments in "genomics," toxicology and much of biological science, is faced with previously undreamed of opportunities and equally daunting challenges. The ability to generate the large quantities of data becoming routinely available could not be imagined a decade ago. The complexities of data analysis are increasingly the rate-limiting element in scientific advances. The expectations that these large scientific investments will reduce the incidence of human disease and improve health are very high. An emphasis on genetic variation and Toxicogenetics is expected to yield risk estimates for specific rather than average individuals and individuals with varied lifestyles and complex patterns of exposure. Examples from studies of polymorphic variation in DNA repair genes in the healthy population and cancer risk highlight the complexity and challenges of incorporating genetic variation into quantitative estimates of risk associated with environmentally relevant exposures. Similar issues exist in selecting the animal models most appropriate for predicting human risk from environmental exposures to toxic agents.

Key Words: Genetic variation • risk estimation • DNA repair • cancer.

References

  • Ahsan, H., Chen, Y., Wang, Q., Slavkovich, V., Graziano, J.H., and Santella, R.M. (2003). DNA repair gene XPD and susceptibility to arsenic-induced hyperkeratosis. Toxicol Lett 143, 123—31.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Airoldi, L., Pastorelli, R., Magagnotti, C., and Fanelli, R. (1999). Carcinogen-DNA adducts as tools in risk assessment. Adv Exp Med Biol 472, 231—40.[ISI][Medline] [Order article via Infotrieve]
  • Amin, R.P., Hamadeh, H.K., Bushel, P.R., Bennett, L., Afshari, C.A., and Paules, R.S. (2002). Genomic interrogation of mechanism(s) underlying cellular responses to toxicants. Toxicology 181—182, 555—63.[CrossRef]
  • Anderson, J.L., Carlquist, J.F., Horne, B.D., and Muhlestein, J.B. (2003). Cardiovascular pharmacogenomics: current status, future prospects. J Cardiovasc Pharmacol Ther 8, 71—83.[Abstract/Free Full Text]
  • Bernstein, C., Bernstein, H., Payne, C.M., and Garewal, H. (2002). DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat Res 511, 145—78.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Berwick, M., Matullo, G., and Vineis, P. (2002). Studies of DNA repair and human cancer: an update. In Biomarkers of Environmentally Associated Disease: Technologies, Concepts and Perspectives (S. H. Wilson and W. A. Suk, eds.), pp. 84—105. Lewis Publishers, Boca Raton, Florida.
  • Berwick, M., and Vineis, P. (2000). Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. J Natl Cancer Inst 92, 874—97.[Abstract/Free Full Text]
  • Bigbee, W.L., Fuscoe, J.C., Grant, S.G., Jones, I.M., Gorvad, A.E., Harrington-Brock, K., Strout, C.L., Thomas, C.B., and Moore, M.M. (1998). Human in vivo somatic mutation measured at two loci: individuals with stably elevated background erythrocyte glycophorin A (GPA) variant frequencies exhibit normal T lymphocyte hprt mutant frequencies. Mutat Res 397, 119— 36.[ISI][Medline] [Order article via Infotrieve]
  • Bonassi, S., Hagmar, L., Stromberg, U., Montagud, A.H., Tinnerberg, H., Forni, A., Heikkila, P., Wanders, S., Wilhardt, P., Hansteen, I.L., Knudsen, L.E., and Norppa, H. (2000). Chromosomal aberrations in lymphocytes predict human cancer independently of exposure to carcinogens. Cancer Res 60, 1619—25.[Abstract/Free Full Text]
  • Butkiewicz, D., Grzybowska, E., Phillips, D.H., Hemminki, K., and Chorazy, M. (2000). Polymorphisms of the GSTP1 and GSTM1 genes and PAH-DNA adducts in human mononuclear white blood cells. Environ Mol Mutagen 35, 99—105.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Cheo, D.L., Meira L.B., Burns, D.K., Reis, A.M., Issac, T., and Friedberg, E.C. (2000). Ultraviolet B radiation-induced skin cancer in mice defective in the Xpc, Trp53, and Apex (HAP1) genes: genotype-specific effects on cancer predisposition and pathology of tumors. Cancer Res 60, 1580—4.[Abstract/Free Full Text]
  • Cloos, J., Nieuwenhuis, E.J.C., Boomsma, D.I., Kuik, D.J., van der Sterre, M.L.T., Arwert, F., Snow, G.B., and Braakhuis, B.J.M. (1999). Inherited susceptibility to bleomycin-induced chromatid breaks in cultured peripheral blood lymphocytes. J Natl Cancer Inst 91, 1125—30.[Abstract/Free Full Text]
  • Collins, F.S., Brooks, L.D., and Chakravarti, A. (1998). A DNA polymorphism discovery resource for research on human genetic variation. Genome Res 8, 1229—31.[Free Full Text]
  • Cooper, R.S., and Psaty, B.M. (2003). Genomics and medicine: distraction, incremental progress, or the dawn of a new age. Ann Intern Med 138, 576—80.[Abstract/Free Full Text]
  • Cox, N.J. (2001). Challenges in identifying genetic variation affecting susceptibility to type 2 diabetes: examples from the study of calpain-10 gene. Human Mol Genet 10, 2301—5.[Abstract/Free Full Text]
  • Daly, A.K. (2003). Pharmacogenetics of the major polymorphic metabolizing enzymes. Fund Clin Pharmacol 17, 27—41.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Doris, P.A. (2001). Hypertension genetics, single nucleotide polymorphisms, and the common disease: common variant hypothesis. Hypertension 39, 323—31.[CrossRef][ISI]
  • Duell, E.J., Wiencke, J.K., Cheng, T.J., Varkonyi, A., Zuo, Z.F., Ashok, T.D., Mark, E.J., Wain, J.C., Christiani, D.C., and Kelsey, K.T. (2000). Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis 21, 965—71.[Abstract/Free Full Text]
  • Evans, W.E. (2003). Pharmacogenomics: marshalling the human genome to individualise drug therapy. Gut 52, 10—18.[Free Full Text]
  • Evans, W.E., and McLeod, H.L. (2003). Pharmacogenomics—drug disposition, drug targets, and side effects. N Engl J Med 348, 538—49.[Free Full Text]
  • Flockhart, D.A., and Rae, J.M. (2003). Cytochrome P4503A pharmacogenetics: the road that needs traveled. Pharmacogenomics J 3, 3—7.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Friedberg, E.C., Walker, G.C., and Siede, W. (1995). DNA Repair and Mutagenesis. ASM Press, Washington, DC.
  • Garner, R.C. (1998). The role of DNA adducts in chemical carcinogenesis. Mutat Res 402, 67—75.[ISI][Medline] [Order article via Infotrieve]
  • Goode, E.L., Ulrich, C.M., and Potter, J.D. (2002). Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol. Biomarkers Prev 11, 1513—30.[Abstract/Free Full Text]
  • Goss, K.H., Risinger, M.A., Kordich, J.J., Sanz, M.M., Straughen, J.E., Slovek, L.E., Capobianco, A.J., German, J., Boivin, G.P., and Groden, J. (2002). Enhanced tumorformation in mice heterozygous forBlm mutation. Science 297, 2051—3.[Abstract/Free Full Text]
  • Grossman, L., Matanoski, G., Farmer, E., Hedayati, M., Ray, S., Trock, B., Hanfelt, J., Roush, G., Berwick, M., and Hu, J.J. (1999). DNA repair as a susceptibility factor in chronic diseases in human populations. In Advances in DNA Damage and Repair (M. Dizdaroglu and A. E. Karakaya, eds.), pp. 149—167. Kluwer Academic/Plenum Publishers, New York.
  • Gupta, R.C., and Lutz, W.K. (1999). Background DNA damage for endogenous and unavoidable exogenous carcinogens, a basis for spontaneous cancer incidence? Mutat Res 424, 1—8.[ISI][Medline] [Order article via Infotrieve]
  • Hadi, M., Coleman, M., Fidelis, K., Mohrenweiser, H.W., and Wilson, III D.W. (2000). Functional characterization of Ape1 variants identified in the human population. Nucl Acids Res 28, 3871—9.[Abstract/Free Full Text]
  • Hagmar, L., Bonassi, S., Stromberg, U., Brogger, A., Knudsen, L.E., Norppa, H., and Reuterwall, C. (1998). Chromosomal aberrations in lymphocytes predict human cancer: a report from the European Study Group on Cytogenetic Biomarkers and Health (ESCH). Cancer Res 58, 4117—21.[Abstract/Free Full Text]
  • Hemminki, K., Koskinen, M., and Zhao, C. (2001). DNA adducts as a marker for cancer risk? Int J Cancer 92, 923—6.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Hoeijmakers, J.H. (2001). Genome maintenance mechanisms for preventing cancer. Nature 411, 366—74.[CrossRef][Medline] [Order article via Infotrieve]
  • Hopper, J.L. (2001). Genetic epidemiology of female breast cancer. Semin Cancer Biol 11, 367—74.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Hsieh, P. (2001). Molecular mechanisms of DNA mismatch repair. Mutat Res 486, 71—87.[ISI][Medline] [Order article via Infotrieve]
  • Hu, J.J., Smith, T.R., Miller, M.R., Mohrenweiser, H.W., Golden, A., and Case, L.D. (2001). Amino acid substitution variants of APE1 and XRCC1 genes associated with ionizing radiation sensitivity. Carcinogenesis 22, 917—22.[Abstract/Free Full Text]
  • Ihle, J.N. (2000). The challenge of translating knockout phenotypes into gene function. Cell 102, 131—4.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Ingelman-Sundberg, M., and Evans, W.E. (2001). Unraveling the functional genomics of the human CYP2D6 gene locus. Pharmacogenetics 11, 553—4.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Ishikawa, T., Ide, F., Qin, X., Zhang, S., Takahashi, Y., Sekiguchi, M., Tanaka, K., and Nakatsuru, Y. (2001). Importance of DNA repair in carcinogenesis: evidence from transgenic and gene targeting studies. Mutat Res 477, 41—9.[ISI][Medline] [Order article via Infotrieve]
  • Jones, I.M., Galick, H., Kato, P., Langlois, R.G., Mendelsohn, M.L., Murphy, G.A., Pleshanov, P., Ramsey, M.J., Thomas, C.B., Tucker, J.D., Tureva, L., Vorobtsova, I., and Nelson, D.O. (2002). Three somatic genetic biomarkers and covariates in radiation-exposed Russian cleanup workers of the chernobyl nuclear reactor 6-13 years after exposure. Radiat Res 158, 424— 42.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Jones, I.M., Nelson, D.O., Thomas, C.B., Xi, T., and Mohrenweiser, H.M. (2003). Low frequency variants contribute to base excision repair pathway genotype-phenotype relationships. Cancer Res 44, 1337.
  • Jyothish, B., Ankathil, R., Chandini, R., Vinodkumar, B., Nayar, G.S., Roy, D.D., Madhavan, J., and Nair, M.K. (1998). DNA repair proficiency: a potential marker for identification of high risk members in breast cancer families. Cancer Lett 124, 9—13.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Kaina, B., Fritz, G., Ochs, K., Haas, S., Grombacher, T., Dosch, J., Christmann, M., Lund, P., Gregel, C.M., and Becker, K. (1998). Transgenic systems in studies on genotoxicity of alkylating agents: critical lesions, thresholds and defense mechanisms. Mutation Res 405, 179—91.[Medline] [Order article via Infotrieve]
  • Kalow, W. (2001). Pharmacogenetics, pharmacogenomics, and pharmacobiology. Clin Pharm Therap 70, 1—4.[Medline] [Order article via Infotrieve]
  • Kalow, W. (2002). Pharmacogenetics and pesonalized medicine. Fund Clin Pharmacol 16, 337—42.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Kucherlapati, M., Yang, K., Kuraguchi, M. Zhao, J., Lia, M., Heyer, J., Kane, M. F. Fan, K., Russell, R., Brown, A. M., Kneitz, B., Edelmann, W., Kolodner, R. D., Lipkin, M., and Kucherlapti, R. (2002). Haploinsufficiency of Flap endonuclease (Fen1) leads to rapid tumor progression. Proc Natl Acad Sci USA 99, 9924—9.[Abstract/Free Full Text]
  • Kurth, J.H. (2003). Pharmacogenetics-the horizon. Rev Gastroenterol Disord 3, S3—S8.[Medline] [Order article via Infotrieve]
  • Lash, L.H., Hines, R.N., Gonzalez, F.J., Zacharewski, T.R., and Rothstein, M.A. (2003). Genetics and susceptibility to toxic chemicals: do you (or should you) know your genetic profile? J Pharmacol Exp Therap 305, 403—40.[Abstract/Free Full Text]
  • Liang, G., Xing, D., Miao, X., Tan, W., Yu, C., Lu, W., and Lin, D. (2003). Sequence variations in the DNA repair gene XPD and risk of lung cancer in a Chinese population. Int J Cancer 105, 669—73.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Lindahl, T. (1993). Instability and decay of the primary structure of DNA. Nature 362, 709—15.[CrossRef][Medline] [Order article via Infotrieve]
  • Lindpaintner, K. (2003). Pharmacogenetics and the future of medical practice. J Mol Med 81, 141—53.[ISI][Medline] [Order article via Infotrieve]
  • Lutz. W.K. (1999). Dose-response relationships in chemical carcinogenesis reflect differences in individual susceptibility. Consequences for cancer risk assessment, extrapolation, and prevention. Hum Exp Toxicol 18, 707— 12.[Abstract/Free Full Text]
  • Lunn, R.M., Langlois, R.G., Hsieh, L.L., Thompson, C.L., and Bell, D.A. (1999). XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res 59, 2557—61.[Abstract/Free Full Text]
  • Meira, L.B., Devaraj, S., Kisby, G.E., Burns, D.K., Daniel, R.L., Hammer, R.E., Grundy, S., Jialal, I., and Friedberg, E.C. (2001a). Heterozygosity for the mouse Apex gene results in phenotypes associated with oxidative stress. Cancer Res 61, 5552—7.[Abstract/Free Full Text]
  • Meira, L.B., Reis, A.M., Cheo, D.L., Nahari, D., Burns, D.K., and Friedberg, E.C. (2001b). Cancer predisposition in mutant mice defective in multiple genetic pathways: uncovering important genetic interactions. Mutat Res 477, 51—8.[ISI][Medline] [Order article via Infotrieve]
  • Mohrenweiser, H.W., and Jones, I.M. (1998). Variation in DNA repair is a factor in cancer susceptibility: a paradigm for the promises and perils of individual and population risk estimation? Mutat Res 400, 15—24.[ISI][Medline] [Order article via Infotrieve]
  • Mohrenweiser, H.W., Wilson III, D.M., and Jones, I.M. (2003a). Challenges and complexities in estimating both the functional impact and the disease risk associated with the extensive genetic variation in human DNA repair genes. Mutat Res 256, 93—125.
  • Mohrenweiser, H.W., Xi, T., and Jones, I.M. (2003b). Many common amino acid substitutions variants identified in DNA repair genes during population based screenings are predicted to impact protein function. Cancer Res 44, 1337.
  • Mohrenweiser, H.W., Xi, T., Vazquez-Matias, J., and Jones, I.M. (2002). Identification of 127 amino acid substitution variants in screening 37 DNA repair genes in humans. Cancer Epidemiol Biomarkers Prev 11, 1054— 64.[Abstract/Free Full Text]
  • Moller, P., Wallin, H., Dybdahl, M., Frentz, G., and Nexo, B.A. (2000). Psoriasis patients with basal cell carcinoma have more repair-mediated DNA strand-breaks after UVC damage in lymphocytes than psoriasis patients without basal cell carcinoma. Cancer Lett 151, 187—92.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Ng, P.C., and Henikoff, S. (2001). Predicting deleterious amino acid substitutions. Genome Res 11, 863—74.[Abstract/Free Full Text]
  • Ng, P.C., and Henikoff, S. (2002). Accounting for human polymorphisms predicted to affect protein function. Genome Res 12, 436—46.[Abstract/Free Full Text]
  • Nwosu, V., Carpten, J., Trent, J.M., and Sheridan, R. (2001). Heterogeneity of genetic alterations in prostate cancer: evidence of the complex nature of the disease. Hum Mol Genet 10, 2313—8.[Abstract/Free Full Text]
  • Oscarson, M. (2003). Pharmacogenetics of drug metabolizing enzymes: importance for personalized medicine. Clin Chem Lab Med 41, 573—80.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Orphanides, G. (2002). Toxicogenomics: challenges and opportunities. Toxicol Lett 140—141, 145—8.[CrossRef]
  • Patel, R.K., Trivedi, A.H., Arora, D.C., Bhatavdekar, J.M., and Patel, D.D. (1997). DNA repair proficiency in breast cancer patients and their firstdegree relatives. Int J Cancer 73, 20—4.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Peterson, G.M. (2000). Familial aggregation: sorting susceptibility from shared environment. J Natl Cancer Inst 92, 1114—5.[Free Full Text]
  • Peto, J., Easton, D.F., Matthews, F.E., Ford, D., and Swerdlow, A.J. (1996). Cancer mortality in relatives of women with breast cancer: the OPCS study. Int J Cancer 65, 275—83.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Perera, F.P. (2000). Molecular epidemiology: on the path to prevention? J Natl Cancer Inst 92, 602—12.[Abstract/Free Full Text]
  • Phillips, D.H., Farmer, P.B., Beland, F.A., Nath, R.G., Poirier, M.C., Reddy, M.V., and Turteltaub, K.W. (2000). Methods of DNA adduct determination and their application to testing compounds for genotoxicity. Environ Mol Mutagen 35, 222—33.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Ponder, B.A.J. (2001). Cancer genetics. Nature 411, 336—41.[CrossRef][Medline] [Order article via Infotrieve]
  • Povey, A.C. (2000). DNA adducts: endogenous and induced. Toxicol Pathol 28, 405—14.[Abstract/Free Full Text]
  • Povirk, L.F. (1996). DNA damage and mutagenesis by radiomimetic DNA-cleaving agents: bleomycin, neocarzinostatin and other enediynes. Mutat Res 355, 71—89.[ISI][Medline] [Order article via Infotrieve]
  • Qiao, Y., Spitz, M.R., Guo, Z., Hadeyati, M., Grossman, L., Kraemer, K.H., and Wei, Q. (2002a). Rapid assessment of repair of ultraviolet DNA damage with a modified host-cell reactivation assay using a luciferase reporter gene and correlation with polymorphisms of DNA repair genes in normal human lymphocytes. Mutat Res 509, 165—74.[ISI][Medline] [Order article via Infotrieve]
  • Qiao, Y., Spitz, M.R., Shen, H., Guo, Z., Shete, S., Hedayati, M., Grossman, L., Mohrenweiser, H., and Wei, Q. (2002b). Modulation of repair of ultraviolet damage in the host-cell reactivation assay by polymorphic XPC and XPD/ERCC2 genotypes. Carcinogenesis 23, 295—99.[Abstract/Free Full Text]
  • Ramensky, V., Bork, P., and Sunyaev, S. (2002). Human non-synonymous SNPs: server and survey. Nucl Acids Res 30, 3894—900.[Abstract/Free Full Text]
  • Ratnasinghe, D.L., Yao, S.X., Forman, M., Qiao, Y.L., Andersen, M.R., Giffen, C.A., Erozan, Y., Tockman, M.S., and Taylor, P.R. (2003). Gene-environment interactions between the codon 194 polymorphism of XRCC1 and antioxidants influence lung cancer risk. Anticancer Res 23, 627—32.[ISI][Medline] [Order article via Infotrieve]
  • Risch, N.J. (2000). Searching for genetic determinants in the new millennium. Nature 405, 847—56.[CrossRef][Medline] [Order article via Infotrieve]
  • Risch, N.J. (2001). The genetic epidemiology of cancer: interpreting family and twin studies and their implications for molecular genetic approaches. Cancer Epidemiol Biomarkers Prev 10, 733—41.[Abstract/Free Full Text]
  • Roberts, S.A., Spreadborough. A.R., Bulman, B., Barber, J.B.P., Evans, D.G.R., and Scott, D. (1999). Heritability of cellular radiosensitivity: a marker of low-penetrance predisposition genes in breast cancer. Am J Hum Genet 65, 784—94.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Rogers, J.F., Nafziger, A.N., and Bertino, J.S. (2002). Pharmacogenetics affects dosing, efficacy, and toxicity of Cytochrome P450-Metabolized drugs. Excerpta Medica 113, 746—50.
  • Rothman, N., Wacholder, S., Caporaso, N.E., Garcia-Closas, M., Buetow, K., and Fraumeni, Jr. J.F. (2001) The use of common genetic polymorphisms to enhance the epidemiologic study of environmental carcinogens. Biochim Biophys Acta 1471, C1—C10.[Medline] [Order article via Infotrieve]
  • Sachidanandam, R., Weissman, D., Schmidt, S.C., Kakol, J.M., Stein, L.D., et al. (2001). A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409, 928—33.[CrossRef][Medline] [Order article via Infotrieve]
  • Savas, S., Knight, J.A., Briollais, L., and Ozcelik, H. (2002). Prediction of deleterious single nucleotide polymorphisms (SNPs) in DNA repair genes for breast cancer association studies. Cancer Epidemiol Biomarkers Prev 11, 1178s.
  • Sellers, T.A., Potter, J.D., Bailey-Wilson, J.E., Rich, S.S., Rothschild, H., and Elston, E.R. (1992). Lung cancer detection and prevention: Evidence for interaction between smoking and genetic predisposition. Cancer Res 52, 2694—7.
  • Shen, M.J., Jones, I., and Mohrenweiser, H.W. (1998). Non-conservative amino acid substitutions exist at polymorphic frequency in DNA repair genes. Cancer Res 58, 604—8.[Abstract/Free Full Text]
  • Shi, M.M., Bleavins, M.R., and de La Iglesia, F.A. (2001). Pharmacogenetic application in drug development and clinical trials. Drug Metab. Disposit 29, 591—5.[Abstract/Free Full Text]
  • Shields, P.G., and Harris, C.C. (2000). Cancer risk and low-penetrance susceptibility genes in gene environment interactions. J Clin Oncol 18 2309—15.[Abstract/Free Full Text]
  • Siest, G., Ferrari, F., Accaoui, M.J., Batt, A.M., and Visvikis, S. (2003). Pharmacogenomics of drugs affecting the cardiovascular system. Clin Chem Lab Med 41, 590—9.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Smith, T.R., Miller, M.S., Lohman, K., Lange, E.M., Case, L.D., Mohrenweiser, H.W., and Hu J.J. (2003). Polymorphisms of XRCC1 and XRCC3 genes and susceptibility to breast cancer. Cancer Lett 190, 183—90.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Spring, K., Ahangari, F., Scott, S.P., Waring, P., Purdie, D.M., Chen, P.C., Hourigan, K., Ramsay, J., McKinnon, P.J., Swift, M., and Lavin, M.F. (2002). Mice heterozygous for mutation in Atm, the gene involved in ataxia- telangiectasia, have heightened susceptibility to cancer. Nature Genet 32, 185—90.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Steinke, J.W., Borish, L., and Rosenwasser, L.J. (2003). Genetics of hypersensitivity. J Allergy Clin Immunol 111, 495—501.[CrossRef]
  • Sunyaev, S., Ramensky, V., Koch, I., Lathe, W., Kondrashov, A.S., and Bork, P. (2001). Prediction of deleterious human alleles. Hum Mol Genet 10, 591—7.[Abstract/Free Full Text]
  • Thomas, C.B., Nelson, D.O., Pleshanov, P., Vorobstova, I., Tureva, L., Jensen, R., and Jones I.M. (1999). Elevated frequencies of hypoxanthine phosphoribosyltransferase lymphocyte mutants are detected in Russian liquidators 6 to 10 years after exposure to radiation from the Chernobyl nuclear power plant accident. Mutat Res 439, 105—19.[ISI][Medline] [Order article via Infotrieve]
  • Thompson, L.H., and Schild, D. (2001). Homologous recombinational repair of DNA ensures mammalian chromosome stability. Mutat Res 477, 131—53.[ISI][Medline] [Order article via Infotrieve]
  • Turner, S.T., and Boerwinkle, E. (2003). Genetics of blood pressure, hypertensive complications, and antihypertensive drug responses. Pharmacogenomics 4, 53—65.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Vineis, P. (1997). Molecular epidemiology: low-dose carcinogens and genetic susceptibility. Int J Cancer 71, 1—3.[ISI][Medline] [Order article via Infotrieve]
  • Vineis, P., and Perera, F. (2000). DNA adducts as markers of exposure to carcinogens and risk of cancer. Int J Cancer 88, 325—8.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Vogel, V., Hedayati, M., Dybdahl, M., Grossman, L., and Nexo, B.A. (2001). Polymorphisms of the DNA repair gene XPD: correlations with risk of basal cell carcinoma revisited. Carcinogenesis 22, 899—904.[Abstract/Free Full Text]
  • Wang, Z., and Moult, J. (2001). SNPs, protein structure, and disease. Hum Mutat 17, 263—70.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Weinshilboum, R. (2001). Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. Drug Metab Disposit 29, 601—5.[Abstract/Free Full Text]
  • Weinshilbourn, R. (2003). Inheritance and drug response. N Engl J Med 348, 529—37.[Free Full Text]
  • Welsch, P.L., Owens, K.N., and King, M.C. (2000). Insights into the functions of BRCA1 and BRCA2. Current Opin Genet Develop 7, 46—51.
  • Whyatt, R.M., Perera, F.P., Jedrychowski, W., Santella, R.M., Garte, S., and Bell, D.A. (2000). Association between polycyclic aromatic hydrocarbon-DNA adduct levels in maternal and newborn white blood cells and glutathione S-transferase P1 and CYP1A1 polymorphisms. Cancer Epidemiol Biomarkers Prev 9, 207—12.[Abstract/Free Full Text]
  • Wolf, C.R., Smith, G., and Smith, R.L. (2000). Pharmacogenetics. Brit Med J 320, 987—90.[Free Full Text]
  • Wood, R.D., Mitchell, M., Sgouros, J., and Lindahl, T. (2001). Human DNA repair genes. Science 291, 1284—9.[Abstract/Free Full Text]
  • Worgul, B.V., Smilenov, L., Brenner, D.J., Junk, A., Zhou, W., and Hall, E.J. (2002). Atm heterozygous mice are more sensitive to radiation-induced cataracts than are their wild-type counterparts. Proc Natl Acad Sci USA 99, 9836—9.[Abstract/Free Full Text]
  • Wu, X., Gu, J., Amos, C.I., Jiang, H., Hong, W.K., and Spitz, M.R. (1998a). A parallel study of in vitro sensitivity to benzo[a]pyrene diol epoxide and bleomycin in lung carcinoma cases and control. Cancer 83, 1118—27.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Wu, X., Gu, J., Hong, W.K., Lee, J.J., Amos, C.I., Jiang, H., Winn, R.J., Fu, K.K., Cooper, J., and Spitz, R. (1998b). Benzo[a]pyrene diol epoxide and bleomycin sensitivity and susceptibility to cancer of upper aerodigestive tract. J Natl Cancer Inst 90, 1393—9.[Abstract/Free Full Text]
  • Wu, X., Spitz, M.R., DeAndrade, M., Benowitz, N.L., and Swan, G.E. (2000). Genetic influence on mutagen sensitivity: a twin study. Proc Amer Assoc Cancer Res 41, 437.
  • Wu, X., Zhao, H., Wei, Q., Amos, C.I., Zhang, K., Guo, Z., Qiao, Y., Hong, W.K., and Spitz, M.R. (2003). XPA polymorphism associated with reduced lung cancer risk and a modulating effect on nucleotide excision repair capacity. Carcinogenesis 24, 505—9.[Abstract/Free Full Text]
  • Xu, J., Meyers, D.A., Ober, C., Blumenthal, M.N., Mellen, B., et. al. (2001). Genomewide screen and identification of gene-gene interactions for asthma-susceptibility loci in three U.S. populations: collaborative study of the genetics of asthma. Am J Human Genet 68, 1437—46.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Zanger, U.M., Fischer, J., Raimundo, S., Stuven, T., Evert, B.O., Schwab, M., and Eichelbaum, M. (2001). Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 11, 573—85.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Zhang, Z.F., Morgenstern, H., Spitz, M.R., Tashkin, D.P., Yu, G.P., Hsu, T.C., and Schantz, S.P. (2000). Environmental tobacco smoking, mutagen sensitivity, and head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 9, 1043—9.[Abstract/Free Full Text]
  • Zhou, W., Liu, G., Miller, D.P., Thurston, S.W., Xu, L.L., Wain, J.C., Lynch, T.J., Su, L., and Christiani, D.C. (2003). Polymorphisms in the DNA repair genes XRCC1 and ERCC2, smoking, and lung cancer risk. Cancer Epidemiol Biomarkers Prev 12, 359—65.[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mohrenweiser, H. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mohrenweiser, H. W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?